In the following video, Motley Fool health-care analyst David Williamson highlights one critical asset for pharmaceutical company Celgene (NASDAQ:CELG) -- its management. He gives investors three factors that he sees as essential for the leader of any pharmaceutical company, and tells us how well Celgene's Chairman and CEO Bob Hugin stacks up to those criteria.
David Williamson has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Juno Therapeutics Stock Is Soaring Today
The pharmaceutical industry's long-anticipated consolidation of CAR-T biotech companies may be starting.
Will 2018 Be Celgene Corporation's Best Year Yet?
The answer is yes. And no.
Here's What Celgene's Management Just Said About Its Future
An optimistic outlook could spark interest in the large-cap biotech's shares.